Published in Exp Ther Med on November 19, 2015
EGFR antagonists in cancer treatment. N Engl J Med (2008) 9.68
The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg (2009) 2.96
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol (2007) 2.53
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol (2002) 2.25
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 2.17
Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch Toxicol (2014) 2.13
Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med (2013) 1.69
Minocycline: far beyond an antibiotic. Br J Pharmacol (2013) 1.59
Purpuric drug eruption possibly due to gefinitib (Iressa). Int J Dermatol (2005) 1.51
Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci Transl Med (2013) 1.44
Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol (2008) 1.38
Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst (2009) 1.33
The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol (2006) 1.29
Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One (2013) 1.29
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol (2010) 1.20
Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer (2009) 1.20
Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol (2012) 1.20
EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo. J Invest Dermatol (2009) 1.09
A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis. Radiol Oncol (2013) 1.08
Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer (2003) 1.05
The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol (2011) 0.94
Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor. Acta Derm Venereol (2004) 0.93
Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol (2009) 0.89
Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes. Exp Dermatol (2010) 0.86
Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: 'PRIDE' Complex. Indian J Dermatol (2014) 0.85
The management of EGFR inhibitor adverse events: a case series and treatment paradigm. Int J Dermatol (2012) 0.80
Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol (2004) 0.80
Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. Am J Cancer Res (2014) 0.79
Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGF-receptor inhibition. Swiss Med Wkly (2003) 0.77